CA
Caris Life Sciences, Inc.
CAI · NASDAQ
$29.70 +8.00% (+$2.20)
1M +22.02%
Market Cap $7.77B
P/E Ratio 73.94x
Div. Yield -
ROE 18.77%
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Moderate
5/9Valuation
1 /100
Expensive P/FCF 53.07x
P/E 73.94x
P/B 13.14x
Growth
100 /100
Growing Rev. growth 46.46%
Book val. growth N/A
EPS growth N/A
Profitability
79 /100
Strong Op. margin 15.49%
Gross margin 69.66%
FCF margin 14.80%
Quality
79 /100
Excellent ROA 8.55%
ROIC 14.69%
Asset turnover 0.80x
Debt
78 /100
Low Int. coverage 3.24x
Debt/Equity 0.76x
Net debt/EBITDA -1.38x
Stability
41 /100
Moderate EPS volatility 39.17%
Beta 0.68x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about CAI
Online
Sector
Healthcare
Industry
Biotechnology
CEO
David Dean Halbert
Employees
1,846
Headquarters
Irving
Upcoming events
04 NOV
Earnings
Upcoming earnings report